News

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...
The US, a critical market for the pharmaceutical industry, accounted for 44% of AstraZeneca’s total revenue in the second ...
AstraZeneca’s revenues beat expectations for the second quarter, powered by record growth in its all-important US business.
Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...
AstraZeneca pledges $50bn US investment ahead of drugs tariffs - Donald Trump is expected to announce tariffs of up to 200% ...
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...
The FTSE 100 has started higher, up 13 points to 9,094 in a mixed early trading for European markets. Games Workshop Group ...
British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...
AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...
With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...
On a per-share basis, the Cambridge, Britain-based company said it had net income of 79 cents. Earnings, adjusted for non-recurring costs, came to $1.09 per share. The results met Wall Street ...
The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...